Theranostic Pipeline Leveraging the Power of Targeted Alpha-Particles
Targeted Alpha-Particle Radiotherapy for Cancer
We are developing a pipeline of radiotherapies designed to deliver powerful alpha radiation directly to cancer cells utilizing specialized targeting peptides. We are also developing complementary diagnostics that utilize the same targeting peptide to provide the opportunity to understand which patients may respond to therapy.
We Are Developing a New Class of “Theranostics” to Treat Cancer
Targeted Theranostics Provide the Potential to Improve Efficacy and Minimize Toxicity
Through the use of proprietary, specialized targeting peptides, we are able to diagnose and then deliver our powerful alpha-particle radiotherapy directly to the tumor. Utilizing a radioactive imaging agent, Pb-203, connected to a specific targeting peptide, we have the ability to diagnose the tumor. Following diagnosis, we link our alpha-particle radioactive isotope, Pb-212, to the same targeting peptide to treat and potentially kill the tumor. This two-step, personalized medicine approach offers the ability to understand which patients may respond to our therapy and potentially improve efficacy while minimizing toxicity associated with many other types of cancer treatments.
VMT01 is in development for the treatment and diagnosis of metastatic melanoma. Through the use of a specialized peptide, VMT01 is designed to target the melanocortin 1 receptor (MC1R) on tumor cells. VMT01 is currently being evaluated in a Phase 1 imaging study being conducted at the Mayo Clinic Rochester. Following the results of the imaging trial, the Company plans to initiate a Phase 1/2a therapy study.
VMT-𝛼-NET is in development for the treatment and diagnosis of somatostatin receptor subtype 2 (SSTR2). VMT-𝛼-NET is expected to enter a Phase 1 imaging study in Q3, 2021 that will be conducted at the University of Iowa Hospitals and Clinics.